Related Experiment Video
Updated: Mar 30, 2026
06:18
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
3.9K
Chimeric antigen receptor T cell therapy: 25years in the making
Saar Gill1, Marcela V Maus1, David L Porter1
1Division of Hematology/Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA.
Blood Reviews
|November 18, 2015
Summary
Chimeric antigen receptor (CAR) T cell therapy has advanced significantly, moving from concept to clinical reality. This review details CAR T cell therapy
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T cell therapy represents a significant advancement in cancer treatment.
- Over 25 years, progress in molecular biology, virology, and manufacturing has enabled its clinical translation.
- CAR T cell therapy has evolved from a research concept to a viable treatment option.
Purpose of the Study:
- To explain the preclinical concept of CAR T cell therapy.
- To outline the clinical translation of CAR T cell therapy.
- To provide insights from early clinical applications for practicing clinicians.
Main Methods:
- Review of preclinical CAR T cell therapy concepts.
- Analysis of clinical translation pathways.
- Synthesis of lessons learned from initial CAR T cell therapy trials.
Main Results:
- CAR T cell therapy has transitioned from a scientific curiosity to a clinical reality.
- Advances in key scientific and manufacturing areas have driven this progress.
- Early clinical experiences offer valuable lessons for practitioners.
Conclusions:
- CAR T cell therapy is a rapidly developing field with significant clinical impact.
- Understanding its preclinical basis and clinical journey is crucial for effective implementation.
- Ongoing learning from clinical practice will further refine CAR T cell therapy.
